MiMedx Group (NASDAQ:MDXG) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

MiMedx Group (NASDAQ:MDXG) announced its quarterly earnings data on Wednesday. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.02), FiscalAI reports. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%. The business had revenue of $58.99 million during the quarter, compared to analyst estimates of $69.47 million.

Here are the key takeaways from MiMedx Group’s conference call:

• The company reported Q1 net sales of $59 million (down 33% YoY), with surgical +13% and wound -60%, an adjusted EBITDA loss of $12 million, and roughly $142 million net cash at quarter end.
• MiMedx says the steep wound-care decline stems from CMS reimbursement changes (ASP?fixed-price cap), the abrupt non?implementation of LCDs, and a problematic WISeR prior?authorization rollout that has severely slowed claims processing and provider utilization.
• The surgical franchise remains the growth engine—Q1 surgical sales grew 13%, the business is up ~50% over three years, and the company launched new products (AmnioFix Thyroid Shield, G4Derm Plus, HydroLix) while completing the EPIEFFECT RCT and PRP market release.
• Management implemented ~$40 million of annualized cost saves (including a ~15% workforce reduction and a ~$4 million Q2 charge) and expects sequential recovery to reach profitability starting in Q3 with full?year adjusted EBITDA roughly break?even and guidance of $260–290 million in revenue.
• Balance sheet and capital actions: MiMedx emphasizes a strong cash position and has a board?authorized $100 million share repurchase program while retaining flexibility for M&A and opportunistic buybacks.

MiMedx Group Trading Down 9.1%

MDXG traded down $0.31 during mid-day trading on Wednesday, hitting $3.09. The stock had a trading volume of 3,412,874 shares, compared to its average volume of 1,190,938. The stock’s fifty day simple moving average is $4.16 and its 200-day simple moving average is $5.65. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.32 and a quick ratio of 3.92. The firm has a market capitalization of $459.07 million, a price-to-earnings ratio of 9.66 and a beta of 1.65. MiMedx Group has a 1-year low of $3.03 and a 1-year high of $7.99.

Institutional Investors Weigh In On MiMedx Group

Several hedge funds have recently bought and sold shares of the company. SkyView Investment Advisors LLC raised its holdings in MiMedx Group by 3.6% in the second quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after purchasing an additional 3,032 shares during the period. Rafferty Asset Management LLC raised its holdings in MiMedx Group by 4.6% in the fourth quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock worth $469,000 after purchasing an additional 3,064 shares during the period. Aviva PLC raised its holdings in MiMedx Group by 4.7% in the fourth quarter. Aviva PLC now owns 71,234 shares of the company’s stock worth $482,000 after purchasing an additional 3,211 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in MiMedx Group by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after purchasing an additional 4,049 shares during the period. Finally, AQR Capital Management LLC raised its holdings in MiMedx Group by 42.6% in the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after purchasing an additional 4,296 shares during the period. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on MDXG shares. Wall Street Zen lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Citizens Jmp restated a “market outperform” rating and issued a $7.00 price objective (down from $10.00) on shares of MiMedx Group in a report on Monday, April 20th. Cantor Fitzgerald cut their price objective on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Lake Street Capital cut their price objective on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 20th. Finally, Citigroup started coverage on shares of MiMedx Group in a report on Monday, February 23rd. They issued a “market outperform” rating on the stock. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, MiMedx Group has an average rating of “Moderate Buy” and an average price target of $8.67.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.